China’s Original HER2 ADC Botuzumab (Shutai Lai®) Prescriptions Launched, Opening a New Chapter in HER2 Positive Breast Cancer Treatment
Introduction The field of anti-tumor treatment in China has reached a significant milestone—the first domestically developed HER2 antibody-drug conjugate (ADC) Botuzumab (Shutai Lai®) for the treatment of HER2 positive breast cancer, which can be widely used in second-line and above therapies, has been prescribed in multiple top hospitals across the country.This marks the official entry … Read more